9. REFERÊNCIAS BIBLIOGRÁFICAS

Abram, U.; Alberto, R. **Technetium and Rhenium – Coordination Chemistry and Nuclear Medical Applications.** J. Braz. Chem. Soc., Vol. 17, No. 8, 1486-1500, 2006.

Al-Kady, A. S. et al. **Nanostructure-loaded mesoporous silica for controlled release of coumarin derivatives: A novel testing of the hyperthermia effect.** European Journal of Pharmaceutics and Biopharmaceutics 77 (2011) 66–74.

Andersson, J et al. **Sol–gel synthesis of a multifunctional, hierarchically porous silica/apatite composite.** Biomaterials 26 (2005) 6827–6835.

Andresen, T. L.; Jensen S. S.; Jorgensen, K. **Advanced strategies in liposomal cancer therapy: Problems and prospects of active and tumor specific drug release.** Progress in Lipid Research 44 (2005) 68–97.

Ballas, F. et al. **Confinement and controlled release of bisphosphonates on ordered mesoporous silica-based materials.** J. Am. Chem. Soc. 2006, 128, 8116-8117.

Bang, L.T. et al. **Effect of silicon and heat-treatment temperature on the morphology and mechanical properties of silicon - substituted hydroxyapatite.** Ceramics International 37 (2011) 3637–3642.

Bartholoma, M. **Single amino acid chelates (SAAC): a strategy for the design of technetium and rhenium radiopharmaceuticals.** Chem. Commun., 2009, 493–512 | 495.

Beck, J.S. **A new family of mesoporous molecular sieves prepared with liquid crystal templates.** J. Am Chem. Society, Vol. 114, No. 27, 1992.

Billinghurst, M. W.; Jette, D.; Somers, E. **Investigation of the interaction of hydroxyapatite with technetium in association with stannous pyrophosphate.** The International Journal of Applied Radiation and Isotopes Volume 32, Issue 8, August 1981, Pages 559–566.

Bolhassani, A. **Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer.** Biochimica et Biophysica Acta 1816 (2011) 232–246.

Borówka, A.; Szcześ, A. **Synthesis of a novel silica/apatite mesoporous nanocomposite.** Materials Letters 65 (2011) 175–178.

Burgos, A. E. et al. **Controlled release of rhodium (II) carboxylates and their association complexes with cyclodextrins from hydroxyapatite matrix.** Biomaterials 23 (2002) 2519–2526.

Chiola, V.; Ritsko, J.E.; Vanderpool C.D. US Patent No. 3 556 725, 1971.

Cho, M., et al. **The impact of size on tissue distribution and elimination by single intravenous injection of silica nanoparticles.** Toxicol. Lett, May 3.

Chung, T.-H. et al. **The effect of surface charge on the uptake and biological function of mesoporous silica nanoparticles in 3T3-L1 cells and human mesenchymal stem cells.** Biomaterials 28 (2007) 2959–2966.

Colilla, M.; Izquierdo-Barba I.; Vallet-Reggí, M. **Phosphorus-containing SBA-15 materials as bisphosphonate carriers for osteoporosis treatment.** Microporous and Mesoporous Materials 135 (2010) 51–59.

Cuenca A.G. et al. **Emerging Implications of Nanotechnology on Cancer Diagnostics and Therapeutics.** Cancer August 1, 2006 / Volume 107 / Number 3.

Cukierman, E.; Khan, D.R. **The benefits and challenges associated with the use of drug delivery systems in cancer therapy.** Biochemical Pharmacology 80 (2010) 762–770.

DaPieve, C.; Perkins, A.C.; Missailidis, S. **Anti-MUC1 aptamers: radiolabelling with 99mTc and biodistribution in MCF-7 tumour-bearing mice.** Nuclear Med Biol (2009) 36: 703-710.

de Araújo et al. **Síntese da hidroxiapatita e refinamento estrutural por difração de raios-X.** Quim. Nova, Vol. 30, No. 8, 1853-1859, 2007.

DeMuth, P. et al. **Mesoscale porous silica as drug delivery vehicles: Synthesis, characterization, and pH-sensitive release profiles.** Microporous and Mesoporous Materials 141 (2011) 128–134.

Dewanjee M. K. **The chemistry of 99mTc-labeled radiopharmaceuticals.** Semin Nucl Med 1990;20: 5-27.

Díaz, A. et al. **Gorwth of hydroxyapatite in a biocompatible mesoporous ordered silica.** Acta Biomaterialia 2 (2006) 173–179.

Disponível em: **http://www2.inca.gov.br/wps/wcm/connect/cancer/site/oquee/** acesso em 16/01/2012.

Disponível em **http://www.inca.gov.br/conteudo_view.asp?ID=322** acesso em: 16/01/2012.

Doadrio, J.C. et al. **Functionalization of mesoporous materials with long alkyl chains as a strategy for controlling drug delivery pattern.** J. Mater. Chem., 2006, 16, 462–466.

El Shafei, G.M.S.; Philip, C.A.; Moussa, N.A. **Fractal analysis of hydroxyapatite from isotherms.** Journal of Colloid and Interface Science 277 (2004) 410–416.

El-Mabhouh, A.A. et al. **A ^{99m}Tc-labeled gemcitabine bisphosphonate drug conjugate as a probe to assess the potential for targeted chemotherapy of metastatic bone cancer.** Nuclear Medicine and Biology 33 (2006) 715– 722.

Elliott, J. C. **Studies in inorganic chemistry 18 - Structure and chemistry of the apatites and other calcium orthophosphates.** 1994 Elsevier. Página 127.

Faraji, A. H.; Wipf, P. **Nanoparticles in cellular drug delivery.** Bioorganic and Medicinal Chemistry 17 (2009) 2950–2962.

Ferreira C. S. M., et al. **Phototoxic aptamers selectively enter and kill epithelial cancer cells.** Nucleic Acids Res. (2009); 37(3): 866–876.

Garcia, M. et. al. Global **Cancer Facts & Figures 2007.** Atlanta, GA: American Cancer Society, 2007.

Gasser, G. et al. **Preparation, 99mTc-labeling and biodistribution studies of a PNA oligomer containing a new ligand derivative of 2,2′-dipicolylamine.** Journal of Inorganic Biochemistry 104 (2010) 1133–1140.

Gendler, S. J. et al. **MUC1, the renaissance molecule.** J Mammary Gland Biol Neoplasia 2001;6:339–5.

Hamoudeha, M. et al. **Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer.** Advanced Drug Delivery Reviews, Volume 60, Issue 12, 15 September 2008, Pages 1329-1346.

Han, Y-J.; Stucky, G. D.; Butler, A. **Mesoporous Silicate Sequestration and Release of Proteins.** J. Am. Chem. Soc., 1999, 121, 9897-9898.

Handbook of Radiopharmaceuticals: Radiochemistry and Applications. Edited by Michael J. Welch and Carol S. Redvanly Copyright 2003 John Wiley & Sons, Ltd. ISBN: 0-471-49560-3.

He, Q. et al. **A pH-responsive mesoporous silica nanoparticles-based multi-drug delivery system for overcoming multi-drug resistance.** Biomaterials 32 (2011) 7711-7720.

Hench, L. L. **Sol-gel materials for bioceramics applications.** Current opinion in solid state and materials science, Vol. 2, issue 5 1997 – 604-610.

Hench, L. L., et al. **Bonding mechanisms at the interface of ceramic prosthetic materials.** J. Biomed. Muter. Res., 2 (1972) 117-141.

Hench, L. L.; Jones, J. R.; Sepulveda, P. **Bioactive materials for tissue engineering scaffolds. Future strategies for tissue and organ replacement.** Imperial College Press. Disponível em http://www.worldscibooks.com/lifesci/p252.html.

Hench, L. L.; Wheeler D. L.; Greenspan D. C. **Molecular control of bioactivity in sol–gel glasses.** J Sol–Gel Sci Technol 1998; 13:245–50.

Hudson, S. P. et al. **The biocompatibility of mesoporous silicates.** Biomaterials 29 (2008) 4045–4055.

Instituto Nacional de Câncer José Alencar Gomes da Silva. Coordenação Geral de Ações Estratégicas. Coordenação de Prevenção e Vigilância. **Estimativa 2012: incidência de câncer no Brasil** / Instituto Nacional de Câncer José Alencar Gomes da Silva, Coordenação Geral de Ações Estratégicas, Coordenação de Prevenção e Vigilância. – Rio de Janeiro : Inca, 2011. 118 p.

Izquierdo-Barba, I. et al. **In vitro stability of SBA-15 under physiological conditions.** Microporous and Mesoporous Materials 132 (2010) 442–452.

Izquierdo-Barba, I. et al. **Influence of mesoporous structure type on the controlled delivery of drugs: release of ibuprofen from MCM-48, SBA-15 and functionalized SBA-15.** J Sol-Gel Sci Technol (2009) 50:421-429.

Izquierdo-Barba, I. et al. **Release evaluation of drugs from ordered three-dimensional silica structures.** European Journal of Pharmaceutical Sciences 26 (2005) 365–373.

Izquierdo-Barba, I. et al. **Tissue regeneration: A new property of mesoporous materials.** Solid State Sciences 7 (2005) 983–989.

Kawachi, E. Y. et al. **Biocerâmicas: tendências e perspectivas de uma área interdisciplinar.** Química nova, 23(4) (2000).

Kresge T. et al. **Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism.** Nature 359 (1992) 710.

Kruk, M. et al. **Characterization of the Porous Structure of SBA-15.** Chem. Mater. 2000, 12, 1961-1968.

Kumta, P. N. et al. **Nanostructured calcium phosphates for biomedical applications: novel synthesis and characterization.** Acta Biomaterialia 1 (2005) 65–83.

Lara, S. et al. **Multi-functional nanocarriers to overcome tumor drug resistance.** Cancer Treatment Reviews (2008) 34, 592– 602.

Li, X. et al. **Preparation of mesoporous calcium doped silica spheres with narrow size dispersion and their drug loading and degradation behavior.** Microporous and Mesoporous Materials 102 (2007) 151–158.

Lin, Y.-S., et al. **Well-Ordered Mesoporous Silica Nanoparticles as Cell Markers.** Chem. Mater., Vol. 17, No. 18, 2005.

Liu, S. **The role of coordination chemistry in the development of target specific radiopharmaceuticals.** Chemical Society Review, 2004, 33, 445–461.

Liu, Y. et al. **A simple route to hydroxyapatite nanofibers.** Materials Letters 56 (2002) 496–501.

Locardi, B. ET AL. **Thermal behaviour of hydroxyapatite intended for medical applications.** Biomaterials 1993, Vol. 14 No. 6.

López-Noriega, A. **Ordered Mesoporous Bioactive Glasses for Bone Tissue Regeneration.** Chem. Mater., Vol. 18, No. 13, 2006.

Lu, J. et al. **Mesoporous Silica Nanoparticles as a Delivery System for Hydrophobic Anticancer Drugs.** Small 2007, 3, No. 8, 1341 – 1346

Malafaya P.B. et al. **Drug delivery therapies I General trends and its importance on bone tissue engineering applications.** Current Opinion on Solid State Materials Science 6 (2002) 283–295.

Mellaerts, R. et al. **Aging behavior of pharmaceutical formulations of itraconazole on SBA-15 ordered mesoporous silica carrier material.** Microporous and Mesoporous Materials 130 (2010) 154–161.

Meynen, V.; Cool, P.; Vansant, E.F. **Verified syntheses of mesoporous materials.** Microporous and Mesoporous Materials 125 (2009) 170–223.

Muñoz, B. et al. **MCM-41 Organic Modification as Drug Delivery Rate Regulator.** Chem. Mater., Vol. 15, No. 2, 2003

Nieto, A. et al. **Functionalization degree of SBA-15 as key factor to modulate sodium alendronate dosage.** Microporous and Mesoporous Materials 116 (2008) 4–13.

Onida, B. et al. **Incorporation of ordered mesoporous silica inside a bioactive scaffold in view of controlled drug release.** Studies in surface science and catalysis, Volume 158, Part B, 2005, Pages 2027–2032.

Park, J. H. et al. **Biodegradable luminescent porous silicon nanoparticles for in vivo applications.** Nat. Mater. (2009) 8, 331–336.

Parveen S., Misra, R. Sahoo, S.K. **Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging.** Nanomedicine: Nanotechnology, Biology, and Medicine xx (2011) xxx–xxx.

Pasqua, L. et al. **Preparation of bifunctional hybrid mesoporous silica potentially useful for drug targeting.** Microporous and mesoporous materials 103 (2007) 166-173.

Patel, N. et al. **A comparative study on the in vivo behaviour of hydroxyapatite and silicon substituted hydroxyapatite granules.** J Mater Sci Mater Med 2002;13:1199 –1206.

Pei, L. et al. **Effect of drying on the mesoporous structure of sol–gel derived silica with PPO–PEO–PPO template block copolymer.** Journal of Colloid and Interface Science 284 (2005) 222–227.

Pereira, M. M.; Hench, L. L. **Mechanisms of hydroxyapatite formation on porous gel-silica substrates.** J Sol–Gel Sci Technol 1996;7:59–68.

Phan, P. V. et al. **The effect of silicacontaining calcium-phosphate particles on human osteoblasts in vitro.** Journal of Biomed. Mater. Res. 2003;67:1001–8.

Polak, J. M.; Hench, L. L.; Kemp, P. **Future strategies for tissue and organ replacement.** London: Imperial College Press; 2002. p. 3–24. – 56

Ponder. S. M. et al. **Surface Chemistry and Electrochemistry of supported Zerovalent Iron Nanoparticles in the Remediation of Aqueous Metal Contaminants.** Chem. Mater., Vol. 13, No. 2, 2001.

Porter, A. E.; Best, S. M.; Bonfield, W. **Ultrastructural comparison of hydroxyapatite and silicon-substituted hydroxyapatite for biomedical applications.** Journal of Biomedical Materials Research (2004) Part A Volume 69A, Issue 4.

Qu, F. et al. **Controlled release of Captopril by regulating the pore size and morphology of ordered mesoporous silica.** Microporous and Mesoporous Materials 92 (2006) 1–9.

Rai, P. et al. **Development and applications of photo-triggered theranostic agents.** Advanced Drug Delivery Reviews 62 (2010) 1094–1124.

Rouquerol, F.; Rouquerol, J.; Sing, K. **Adsorption by Powders and Porous Solids Principles, Methodology and Applications.** Copyright 1999 Elsevier Ltd. Author(s): ISBN: 978-0-12-598920-6.]

Saha, G. B. **Fundamentals of nuclear pharmacy.** 5th ed. 2003, p. cm.

Sahay, G.; Alakhova, D.Y.; Kabanov, A.V. **Endocytosis of nanomedicines.** Journal of Controlled Release 145 (2010) 182–195.

Saravanapavan, P. et al. **Bioactivity of gel glass powders in the CaO–SiO2 system: a comparison with ternary (CaO–P2O5–SiO2) and quaternary glasses (SiO_2–CaO–P_2O_5–Na_2O).** J Biomed Mater Res 2003; 66(A):110–9. – 53.

Shi, X. **Self-assembly of nanohydroxyapatite in mesoporous silica.** J Mater Sci: Mater Med (2008) 19:2933–2940.

Shi, X. et al. **Novel mesoporous silica-based antibiotic releasing scaffold for bone repair.** Acta Biomaterialia 5 (2009) 1697–1707.

Slowing, I.I. et al. **Mesoporous silica nanoparticles as controlled delivery and gene transfection carriers.** Advanced Drug Delivery Reviews, 60 (2008) 1278–1288.

Son, J. S. et al. **Porous hydroxyapatite scaffold with three-dimensional localized drug delivery system using biodegradable microspheres.** Journal of Controlled Release 153 (2011) 133–140.

Sopyan, I. et al. **Porous hydroxyapatite for artificial bone applications.** Science and Technology of Advanced Materials 8 (2007) 116–123.

Sousa, A. et al. **Mesoporus Silica/Apatite Nanocomposite: Special Route to Control Drug Delivery.** Acta Biomaterialia 4 (2008) 671–679).

Sudimack, J.; Lee, R. J. **Targeted drug delivery via the folate receptor.** Advanced Drug Delivery Reviews 41 (2000) 147 –162.

Szymura-Oleksiak, J. et al. **The kinetics of pentoxifylline release in vivo from drug-loaded hydroxyapatite implants.** Ceramics International 27 (2001) 767–772.

Taguchi, A. Schuth, F. **Ordered mesoporous materials in catalysis.** Microporous and Mesoporous Materials 77 (2005) 1–45.

Thomas, M. J. K. et al. **Inclusion of poorly soluble drugs in highly ordered mesoporous silica nanoparticles.** International Journal of Pharmaceutics 387 (2010) 272–277.

Trewyn, B. G. et al. **Biocompatible mesoporous silica nanoparticles with different morphologies for animal cell membrane penetration.** Chemical Engineering Journal 137 (2008) 23–29.

Trikha, M.; Yan, Li; Nakada, M.T. **Monoclonal antibodies as therapeutics in oncology.** Current opinion in biotechnology, Volume 13, Issue 6, 1 December 2002, Pages 609–614.

Vallet-Regi, M. et al. **A new property of MCM-41: Drug delivery system.** Chem. Mater., Vol. 13, No. 2, 2001.

Vallet-Regí, M. et al. **Phosphorous-doped MCM-41 as bioactive material.** Solid State Sciences 7 (2005) 233–237.

Vallet-Regí, M. et al. **Bioceramics and pharmaceuticals: A remarkable synergy.** Solid State Sciences 9 (2007) 768–776.

Vallet-Regi, M. **Nanostructured mesoporous silica matrices in nanomedicine.** Journal of internal medicine 267 (2010); 22-43.

Van der Vort, P. et al. **Plugged hexagonal templated silica: a unique micro- and mesoporous composite material with internal silica nanocapsules.** Studies in Surface Science and Catalysis Volume 141, 2002, Pages 45–52.

Verstraete, J. et al. **Amorphisation mechanism of a flint aggregate during the alkali–silica reaction: X-ray diffraction and X-ray absorption XANES contributions.** Cement and Concrete Research 34 (2004) 581–586.

Wang, S. **Ordered mesoporous materials for drug delivery.** Microporous and mesoporous materials 117 (2009) 1-9.

Wang, T.; Dorner-Reisel, A.; Muller, E. **Thermogravimetric and thermokinetic investigation of the dehydroxylation of a hydroxyapatite powder.** Journal of the European Ceramic Society 24 (2004) 693–698.

WHO. **Causes of death 2008 summary tables.** Disponível em http://www.who.int/evidence/bod.

Witasp, E. et al. **Efficient internalization of mesoporous silica particles of different sizes by primary human macrophages without impairment of macrophage clearance of apoptotic or antibody-opsonized target cells.** Toxicology and Applied Pharmacology 239 (2009) 306–319.

Xia, W.; Chang J. **Well-ordered mesoporous bioactive glasses (MBG): A promising bioactive drug delivery system.** Journal of Controlled Release 110 (2006) 522–530.

Xia, W.; Chang, J. **Preparation, in vitro bioactivity and drug release property of well-ordered mesoporous 58S bioactive glass.** Journal of Non-Crystalline Solids 354 (2008) 1338–1341.

Xu, R.et al. **Preparation and cell inclusion of From Zeolites to Porous MOF Materials.** The 40th Anniversary of International Zeolite Conference. Elsevier, 2007.

Yu, H.; Zhai Q.-Z. **Mesoporous SBA-15 molecular sieve as a carrier for controlled release of nimodipine.** Microporous and Mesoporous Materials 123 (2009) 298–305.

Zamoume, O. et al. **Macroporous calcium phosphate ceramic implants for sustained drug delivery.** Materials Science and Engineering C 31 (2011) 1352–1356.

Zhao, D. et al. **Morphological Control of Highly Ordered Mesoporous Silica SBA-15.** Chem. Mater. 2000, 12, 275-279.

Zhao, D. et al. **Triblock Copolymer Syntheses of Mesoporous Silica with Periodic 50 to 300 Angstrom Pores.** Science (1998), Vol. 279 23.

Zhao, L.; Yu, J. **Controlled synthesis of highly dispersed TiO2 nanoparticles using SBA-15 as hard template.** Journal of Colloid and Interface Science 304 (2006) 84–91.